Abbott Labs beats by $0.01, beats on revs; guides Q4 EPS in-line (55.06)
- Reports Q3 (Sep) earnings of $0.66 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.65; revenues rose 28.8% year/year to $6.83 bln vs the $6.72 bln Capital IQ Consensus.
- Co issues in-line guidance for Q4, sees EPS of $0.72-0.74, excluding non-recurring items, vs. $0.73 Capital IQ Consensus Estimate.
- Worldwide Diagnostics sales increased 5.4 percent on a reported basis in the third quarter, including a favorable 0.2 percent effect of foreign exchange, and increased 5.2 percent on an operational basis.